Skip to main content

SolV Independent Insurance Associates Announces Commitments to Help Employer Plans Amid Trump's New Drug Pricing Executive Order

-- SolV CEO Scott Kelley urges proactive planning as policy targets global price alignment

SolV Independent Insurance Associates today announced its plans and commitments for guiding employers through prescription drug cost management in light of the new “most-favored-nation” executive order signed May 12 by President Donald J. Trump. As the order drives U.S. reimbursement rates toward international benchmarks, SolV is doubling down on its proven approach to help clients achieve significant savings and clarity amid evolving policy.

“SolV has long educated employers about the disparity between U.S. drug prices and those abroad,” said Scott Kelley, CEO of SolV Independent Insurance Associates. “With U.S. prescriptions costing two to four times more than in other countries, employers need an advocate focused on reducing their largest expenses—not another middleman.”

SolV founder and CEO Scott Kelley noted that the new federal policy mirrors the firm’s long-standing philosophy.

“A key linchpin to the Trump executive order is requiring pharmaceutical companies to honor international pricing for U.S. drug purchases,” Kelley said. “U.S. prescription drugs cost two to four times more than drugs purchased internationally, according to a March 2021 GAO report. SolV has been helping clients tap into international pricing on drugs for years. That’s why it’s important to have the right benefits consultant—someone focused on curbing one of your largest expenses, not adding another middleman to your drug spend.”

While the executive order signals a shift toward greater cost containment, Kelley warns that the path forward will raise complex questions for employers:

“We welcome any attempt to rein in rising healthcare costs,” he said. “But until policies are fully understood and implemented, employers are left grappling with how these changes affect their benefit strategies. That’s where we come in—translating complex policy changes into actionable solutions.”

SolV is doubling down on four core service areas to guide clients through this transition:

  • Transparent Prescription Pricing
    Continuing to structure benefit plans that apply “transparent pricing” opportunities, including international drug pricing, ensuring maximum leverage of available cost containment strategies.
  • Policy Interpretation & Education
    Accelerating webinars, whitepapers, and client briefings to explain how the “most-favored-nation” model will impact formularies, cost structures, and plan design.
  • Compliance & Financial Oversight
    Intensifying review processes to identify additional savings as regulatory details emerge.
  • Personalized Benefit Strategies
    Providing one-on-one consultations that translate policy developments into tailored, compliant solutions for each employer.

“Any move that shines a light on America’s broken prescription pricing system is a step forward,” he said. “Until real savings materialize, we’ll stay focused on what matters most: helping employers navigate these changes effectively.”

SolV will continue to monitor updates to the executive order and provide timely, personalized guidance as the healthcare landscape evolves.

About the company: SolV Independent Insurance Associates is a full-service employee benefits consulting firm founded by CEO Scott H. Kelley in 2016. With offices and representatives in California, Washington, Idaho, North Carolina, Arizona, and New York, SolV supports employers across the U.S. and internationally with expert guidance on employee benefits strategy, compliance, and cost management. Scott Kelley is a Certified Employee Benefits Specialist (CEBS), a designation held by fewer than 2% of employee benefits consultants in the country. For more information, visit www.solvins.com.

Contact Info:
Name: Tess Dumlao
Email: Send Email
Organization: Phoenix PR & Marketing
Website: https://www.phoenixpublicrelations.com

Release ID: 89161087

Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.